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In this commentary, we focus on allergy as a facilitating factor in the pathogenesis of 
alopecia areata (AA). From previous studies on AA, it is well known that subsets of 
patients can have one or more of; seasonal relapse, comorbid atopic rhinitis, asthma 
and dermatitis, lesional infiltrating eosinophils and plasma cells, high levels of total 
IgE, specific IgE for house dust mites (HDM), and/or disrupted skin barrier function 
by the evaluation of filaggrin. Allergy and AA share a similar genetic background; 
both contributing to an immune reaction imbalance. Furthermore, adjunctive 
treatment with antihistamines, or desensitization for HDM, can reduce the severity of 
alopecia in atopic AA patients. Therefore, allergies may contribute to the onset and 
relapse of AA. Identification of an allergic or atopic immune component in AA patient 
subsets may indicate adjunctive treatment intervention measures against allergies 




Several factors are suspected as alopecia areata (AA) disease onset triggers or 
modulators including viruses, stress, and diet.[1-5] The complexity of AA pathogenesis 
and the wide variation in clinical presentations lead us to suggest that multiple 
pathogenetic factors must come together in (un)desirable combinations to induce 
autoimmunity against hair follicle specific antigens.[6,7] As the AA immune response is 
activated systemically, inflammatory cells infiltrate and accumulate in the skin and 
progressively focus on hair follicles.[8,9] If and when a local threshold level of immune 




For subsets of patients, allergy may contribute to systemic activation of autoimmune 
mechanisms. Allergy may also contribute to the local immune response against 




Several items of evidence may link allergy with AA:  
 
1. Seasonal relapse and recovery in AA. Reports suggest first AA onset occurs more 
often in spring and summer;[12] even in horses.[13] Case studies suggest some patients 
exhibit regular seasonal cycling of AA.[14] These reports could reflect seasonal 
changes in allergen exposure, and/or viral load. 
 
2. Comorbid atopic diseases; rhinitis, asthma, dermatitis and food allergy. Atopy 
increases the risk of developing AA.[15,16] Early-onset AA, or alopecia totalis (AT) and 
alopecia universalis (AU), have an increased prevalence concurrent with atopy.[14,17-20] 
Presence of atopy is a poor prognostic factor for AA.[17] Spontaneous chronic urticaria 
has also been linked to AA.[19,21]  
 
3. Mutation of the filaggrin gene related to AA. A filaggrin gene mutation is 
associated with atopic dermatitis and a severe clinical AA subtype.[22,23]  
 
4. Genetic relationships between allergies and AA. GWAS studies show linkage of 
AA to gene pathways also active in atopic/allergic conditions.[24]  
 
5. Elevated serum IgE and AA. High titers of serum IgE have been found in several 
AA studies, even in supposedly non-atopic patients.[25-29] In our own studies, high IgE 
titers correlate to relative resistance to treatment of AA.[30] 
 
6. Eosinophil infiltration in AA lesions. Eosinophils are variably present in AA scalp 
lesions.[8,28,31,32] Previously, we also found plasma cells in the infiltrating cell 
population.[8] Presence of eosinophils may be a favorable prognosis indication for AA 
disease duration.[8] 
  
7. Increased mast cell number and activity in AA. Elevated mast cell numbers are 
present in AA lesions; urticaria may first appear in bald areas of the scalp which 
contain large numbers of mast cells.[33-35] 
 
8. Allergy to dust mites is associated with AA severity. AA patients might have a 
predisposing background which increases the risk of  T cell-driven skin disease 
development.[36] Focusing on house dust mite (HDM) allergy, one of the most 
common allergies in South China, our study suggested allergy to HDM correlates to 
AA severity and early-onset.[8]  
 
9. Desensitization to dust mites can decrease AA severity. In a study conducted by 
our group, AA patients with HDM allergy that received desensitization 
immunotherapy alongside standard treatments for AA (corticosteroids or contact 
sensitization with diphenylcyclopropenone), exhibited a reduced extent of alopecia by 
3 years as compared to AA patients with HDM allergy receiving standard treatments 
alone.[30] The study suggests allergy to HDM may help establish local inflammation in 
a subset of atopic AA patients. 
 
10. Steroid treatment dose for AA is similar to that for allergic diseases. In AA, the 
systemic steroid dosage needed to improve hair growth is relatively low; 0.3- 
0.5mg/kg/day,[37] similar to doses used for allergic rhinitis, but far less than that 
needed in typical autoimmune diseases, such as systemic lupus erythematosus.[38,39] 
 
11. Both Th1 and Th2 type immune responses are present in AA. Immune reaction 
in allergy involves a Th2-dominant pattern, often represented by overexpression of 
IL-4 and IL-5. In contrast, AA is considered a T cell driven, Th1-dominant lesion, 
primarily represented by IFNγ.[40,41] However, both Th1 and Th2 cytokines are 
significantly elevated in AA patients.[42,43] In AA mice both Th1 and Th2 cytokines are 
increased very early in the disease pathogenesis, even in advance of overt hair loss.[44] 
Th2-type cytokines may be associated with the persistence of AA and/or may make 
patients more resistant to successful therapy.[35] 
 
12. Anti-histamines have been successfully used to treat AA. In several reports 
anti-histamine drugs have been shown beneficial for some AA patients.[45-50] Some 
Japanese colleagues confirm they currently use anti-histamines as an adjunctive 
treatment alongside corticosteroids. 
 
Considering the evidence above, allergy may be a constitutional factor in the 
pathogenic process, influencing onset, perpetuation, and relapse of AA.  
 
How to test the hypothesis 
 
Testing the hypothesis may not be straight forward. If allergens trigger AA onset, 
allergen responses need not persist after the trigger event. As with many autoimmune 
diseases, the AA disease mechanism can be self-perpetuating once activated.[51] 
However, if allergen immune responses persist in the AA disease mechanism it should 
be possible to define the significance and whether targeting allergic immune 
responses would help with treating AA. Using mouse models of AA, it may be 
possible to determine whether allergens induce or exacerbate the disease intensity, 
extent, speed of development, or resistance to treatment.[52,53] 
 
With humans, adjunctive treatments against allergies could be used to observe 
whether there is an improved effect on AA resolution. From our observations,[30,43] 
HDM desensitization might modulate the balance of Th1/Th2 cytokine activity in AA. 
Allergen desensitization or antihistamine use in atopic AA patients may not directly 
treat AA, but may change immune activity so as to enable hair growth in response to 
standard treatments.  
 
Relevance and perspectives 
 
Allergy may serve as a facilitating factor in AA pathogenesis, with regards to onset, 
relapse, and severity, in a subset of patients. This is not a new observation,[54] but it 
seems to have been largely disregarded. As our understanding of AA pathobiology 
improves, allergy and/or atopic disease mechanisms may be recognized as playing a 
greater role in AA development and the collapse of hair follicle immune privilege; 
more research is needed to unveil this complicated issue.[55] 
 
In confirming a linkage between allergy and AA, adjunctive intervention measures 
can be taken to improve treatment success for AA patients with atopy (Figure 1). We 
believe that testing for common allergens and desensitizing allergic patients should 
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Figure 1  
 
Figure 1. Summary of atopy in alopecia areata 
 
